Tag Archives: drug

Research IDs potential treatment for deadly, HIV-related blood cancer

The USC team shows that a class of drugs called BET bromodomain inhibitors effectively targets primary effusion lymphoma (PEL), a type of cancer for which those drugs were not expected to be effective. "It’s a reversal of the paradigm," said Preet Chaudhary, chief of the Nohl Division of Hematology and Blood Diseases at the Keck School of Medicine of USC and principal investigator of the study. "Our results suggest that this new class of drug may be an effective treatment for a wider range of cancers than previously thought." PEL is caused by infection with Kaposi’s sarcoma-associated herpes virus, the most common cause of cancer among patients with AIDS. The prognosis for PEL is poor, with a median survival of three to six months. …

Helping RNA escape from cells’ recycling process could make it easier to shut off disease-causing genes

A new study from MIT sheds light on the nanoparticles’ fate and suggests new ways to maximize delivery of the RNA strands they are carrying, known as short interfering RNA (siRNA). "We’ve been able to develop nanoparticles that can deliver payloads into cells, but we didn’t really understand how they do it," says Daniel Anderson, the Samuel Goldblith Associate Professor of Chemical Engineering at MIT. "Once you know how it works, there’s potential that you can tinker with the system and make it work better." Anderson, a member of MIT’s Koch Institute for Integrative Cancer Research and MIT’s Institute for Medical Engineering and Science, is the leader of a research team that set out to examine how the nanoparticles and their drug payloads are processed at a cellular and subcellular level. Their findings appear in the June 23 issue of Nature Biotechnology. …

Diabetes drug points the way to overcoming drug resistance in melanoma

Their studies, conducted in cell and animal models of melanoma, demonstrate that the combined therapy could destroy a subset of drug-resistant cells within a tumor. "We have found that the individual cells within melanoma tumors are not all identical, and tumors contain a sub-population of cells that are inherently drug resistant, which accounts for the fact that advanced melanoma tumors return no matter how much the tumor is depleted," said Meenhard Herlyn, D.V.M., D.Sc., professor and director of Wistar’s Melanoma Research Center. "We found that these slow-growing, drug-resistant cells are marked by a high rate of metabolism, which makes them susceptible to diabetes therapeutics." "Our findings suggest a simple strategy to kill metastatic melanoma — regardless of cell type within the tumor — by combining anticancer drugs with diabetes drug," Herlyn said. "The diabetes drug puts the brakes on the cells that would otherwise repopulate the tumor, thus allowing the anticancer drug to be more effective." In the Cancer Cell article, the researchers describe how various anticancer drugs, including cisplatin and the targeted therapy vemurafenib, which targets melanomas with the BRAF mutation, become more effective when co-delivered with phenformin. …

Dr. Manny: FDA loss of control on Plan B not surprising

I told you so - the government is bamboozling us about Plan B. The Obama administration announced on Monday that it will now allow girls and women of all ages to purchase the Plan B pill without a prescription. This is exactly what I have been warning the American public about. I am now totally convinced that our current federal government loves confusion. When you have a single agenda, and many ways to spin it, the American public never gets a clear answer and that is exactly what has happened with the Plan B emergency contraception controversy. Just last week, a U.S. appeals court ruled that the U.S. Food and Drug Administration (FDA) must make only certain forms of the emergency contraception pill available to children of all ages, without a prescription.  In a confusing ruling, the court stated that while the two-pill version of emergency contraception could be sold over-the-counter to women of all ages, the one-pill version would still only be sold to women age 17 or older. The court did not explain its reasoning. One has to remember that the FDA first approved this form of over-the-counter contraception for women of all ages back in 2011. When that initial FDA ruling came out, there was a loud public outcry and restrictions were quickly put in place barring women under the age of 17 from purchasing these pills. But of course, that was just one spin on the story. In April, a New York judge ruled that restricting access to Plan B was inappropriate, forcing the FDA to reconsider their initial finding that emergency contraception should be available to children of all ages. And then, we got another spin on the story, as the FDA tried to lower the age limit for access to emergency contraception to 15 last month. There was another outcry and more criticism, because we know perfectly well that a 15-year-old may not have a clear understanding of how to utilize emergency contraception. Now, we see that the FDA will get to do what they wanted to do in the first place. How convenient. So, what’s the message here?